Showing 2311-2320 of 5346 results for "".
DERM2020 Content Recap: Brad Glick, DO, MPH
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-brad-glick-do/19840/DERM2020 Faculty Brad Glick, DO, MPH shares his thoughts on DERM2020 and some of the presentations around COVID.Practical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 4
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-4/32760/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss updated guidelines for generalized pustular psoriasis treatment and evaluation in light of the current understanding of the IL-36 pathway, as well as the mechanism of action of spesolimaTreatment Breaks for Super Responders: An Update from the GUIDE Study of Guselkumab in Psoriasis
https://practicaldermatology.com/topics/psoriasis/treatment-breaks-for-super-responders-an-update-from-the-guide-study-of-guselkumab-in-psoriasis/20222/Knut Schäkel, MD, a dermatologist at Heidelberg University Hospital in Germany, shares data on the withdrawal stage of the GUIDE study of guselkumab (Tremfya) in moderate-to-severe plaque psoriasis from his talk at the 2023 European Academy of Dermatology and Venereology meeting in Berlin.DermWireTV: Sanofi Genzyme & Regeneron Global AD Report; Hydroquinone; Pfizer NDA; VCS
https://practicaldermatology.com/topics/practice-management/dermwiretv-sanofi-genzyme-regeneron-global-ad-report-hydroquinone-pfizer-nda-vcs/19868/The “Improving Quality of Care in AD” report, commissioned and funded by Sanofi Genzyme & Regeneron and completed by KPMG, debuts at the annual meeting of the EADV. Changes to FDA regulations implemented as part of the CARES Act limit access to hydroquinone. This year’s Virtual Vegas Cosmetic SuDermWireTV: Latest on Galderma, Eczema Awareness, Hacking Derm, and More
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-latest-on-galderma-eczema-awareness-hacking-derm-and-more/19675/In this week’s edition: Galderma’s Aklief (trifarotene) topical cream is now approved for acne. Sandra Johnson, MD weighs in. Supported by Sanofi and Regeneron in partnership with the National Eczema Association, the Understand AD Squad includes dermatologist Mercedes Gonzalez, MD, who discusses herPractical Dermatology Roundtable: Generalized Pustular Psoriasis, Ch. 2
https://practicaldermatology.com/programs/practical-dermatology/practical-dermatology-roundtable-generalized-pustular-psoriasis-ch-2/32758/Host Neal Bhatia, MD, FAAD, and guests Laura K. Ferris, MD, PhD, FAAD, and Jason E. Hawkes, MD, MS, FAAD, discuss the differences between psoriasis subtypes, the importance of a specialized therapeutic approach targeting the IL-36 pathway for generalized pustular psoriasis, and the role of neutrophiDERM2020 Content Recap: Linda Stein Gold, MD
https://practicaldermatology.com/conferences/dermatology-education-foundation-derm-2020/derm2020-content-recap-linda-stein-gold-md/19845/DERM2020 Faculty Linda Stein Gold, MD discusses what’s new in acne from her presentation during DERM2020.DermwireTV — A big name is getting bigger; ICD-10 looms
https://practicaldermatology.com/videos/dermwire-tv/dermwiretv-mdash-a-big-name-is-getting-bigger-icd-10-looms/19163/In this premiere edition of DermWireTV, from the publishers of Practical Dermatology® magazine, we take a look at the latest acquisition by Valeant Pharmaceuticals, Inc., explore new data for Galderma's Mirvaso for rosacea, and get insights on the ICD-10 code set transition. #DermWireDifferentiating GPP From Plaque Psoriasis for Targeted Therapy
https://practicaldermatology.com/issues/august-2025/differentiating-gpp-from-plaque-psoriasis-for-targeted-therapy/36700/While all types of psoriasis carry significant burdens of disease for patients, certain subtypes have more severe symptoms and require more urgency in diagnosis and treatment. Generalized pustular psoriasis (GPP) is one such subtype and may be considered a disease entity with a classification of itsGuselkumab in PsA: Exploring Patient-Reported Outcomes in Real-World Settings
https://practicaldermatology.com/topics/psoriasis/guselkumab-in-psa-exploring-patient-reported-outcomes-in-real-world-settings/20226/Philip Mease, MD, shares new real-world data showing that psoriatic arthritis patients who take Tremfya (guselkumab) report meaningful improvements in pain, physical function, and fatigue through six months.